These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 26507127)

  • 1. Predictive biomarkers for treatment selection: statistical considerations.
    Chen JJ; Lu TP; Chen YC; Lin WJ
    Biomark Med; 2015; 9(11):1121-35. PubMed ID: 26507127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tutorial in biostatistics: data-driven subgroup identification and analysis in clinical trials.
    Lipkovich I; Dmitrienko A; B R
    Stat Med; 2017 Jan; 36(1):136-196. PubMed ID: 27488683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subgroup identification for treatment selection in biomarker adaptive design.
    Lu TP; Chen JJ
    BMC Med Res Methodol; 2015 Dec; 15():105. PubMed ID: 26646831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for power calculations in predictive biomarker studies in survival data.
    Chen DT; Huang PY; Lin HY; Haura EB; Antonia SJ; Cress WD; Gray JE
    Oncotarget; 2016 Dec; 7(49):80373-80381. PubMed ID: 27661007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment evaluation for a data-driven subgroup in adaptive enrichment designs of clinical trials.
    Zhang Z; Chen R; Soon G; Zhang H
    Stat Med; 2018 Jan; 37(1):1-11. PubMed ID: 28948633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive biomarkers in colorectal cancer: usage, validation, and design in clinical trials.
    Shi Q; Mandrekar SJ; Sargent DJ
    Scand J Gastroenterol; 2012 Mar; 47(3):356-62. PubMed ID: 22181041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Research Techniques Made Simple: Feature Selection for Biomarker Discovery.
    Torres R; Judson-Torres RL
    J Invest Dermatol; 2019 Oct; 139(10):2068-2074.e1. PubMed ID: 31543209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical considerations when analyzing biomarker data.
    Beam CA
    Clin Immunol; 2015 Nov; 161(1):31-6. PubMed ID: 26111480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of subgroup identification methods in clinical drug development: Simulation study and regulatory considerations.
    Huber C; Benda N; Friede T
    Pharm Stat; 2019 Oct; 18(5):600-626. PubMed ID: 31270933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statistical evaluation of a biomarker.
    Ray P; Le Manach Y; Riou B; Houle TT
    Anesthesiology; 2010 Apr; 112(4):1023-40. PubMed ID: 20234303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of drug-induced toxicity biomarkers for treatment determination.
    Lu TP; Chen JJ
    Pharm Stat; 2015; 14(4):284-93. PubMed ID: 25914330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Machine Learning Models for the Identification of Prognostic and Predictive Cancer Biomarkers: A Systematic Review.
    Al-Tashi Q; Saad MB; Muneer A; Qureshi R; Mirjalili S; Sheshadri A; Le X; Vokes NI; Zhang J; Wu J
    Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multistage adaptive biomarker-directed targeted design for randomized clinical trials.
    Gao Z; Roy A; Tan M
    Contemp Clin Trials; 2015 May; 42():119-31. PubMed ID: 25778672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interim treatment selection with a flexible selection margin in clinical trials.
    Wu Y; Zhao PL
    Stat Med; 2013 Jul; 32(15):2529-43. PubMed ID: 23212767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translating predictive biomarkers within oncology clinical development programs.
    Beckman RA; Chen C
    Biomark Med; 2015; 9(9):851-62. PubMed ID: 26330133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flexible alpha allocation strategies for confirmatory adaptive enrichment clinical trials with a prespecified subgroup.
    Sugitani T; Posch M; Bretz F; Koenig F
    Stat Med; 2018 Oct; 37(24):3387-3402. PubMed ID: 29945304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Introduction to the development and validation of predictive biomarker models from high-throughput data sets.
    Deng X; Campagne F
    Methods Mol Biol; 2010; 620():435-70. PubMed ID: 20652515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Finding the (biomarker-defined) subgroup of patients who benefit from a novel therapy: No time for a game of hide and seek.
    McShane LM; Rothmann MD; Fleming TR
    Clin Trials; 2023 Aug; 20(4):341-350. PubMed ID: 37095696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers, subgroup evaluation, and clinical trial design.
    Baker SG; Kramer BS; Sargent DJ; Bonetti M
    Discov Med; 2012 Mar; 13(70):187-92. PubMed ID: 22463794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarker based clinical trial design.
    Simon R
    Chin Clin Oncol; 2014 Sep; 3(3):39. PubMed ID: 25841465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.